Meral Yüksel1, Hacer Kuzu-Okur2, Ayliz Velioğlu-Öğünç1, Zerrin Pelin3. 1. Deparment of Medical Laboratory Technicianship, Vocational School of Health Related Professions, Marmara University, İstanbul, Turkey. 2. Sleep Disorders Unit, Chest Diseases Clinics, Süreyyapaşa Research and Education Hospital, İstanbul, Turkey. 3. Vocational School of Health Related Professions, Gazikent Hasan Kalyoncu University, Gaziantep, Turkey.
Abstract
OBJECTIVE: Obstructive sleep apnea syndrome (OSAS) is associated with increased cardiovascular morbidity and mortality. We aimed to investigate the matrix metalloproteinase-9 (MMP-9) level and MMP-9 gene polymorphism in sleep apnea patients with or without cardiovascular disease. STUDY DESIGN: Case-control study. MATERIAL AND METHODS: Two hundred nine patients [Mean age (±SD), 47 (±12) yrs; M/F, 170/39] diagnosed with sleep-disordered breathing were included in the study. Serum MMP-9 level was performed using enzyme-linked immunosorbant assay (ELISA) and MMP-9 gene polymorphism with polymerase chain reaction-restriction fragment length polymorphism. We divided the patient group into two subgroups: (1) patients with confirmed cardiovascular disease, i.e. CV-P Group and (2) patients without cardiovascular disease, CV-N Group. We compared all parameters between the two groups. RESULTS: There were 56 OSAS patients with cardiovascular disorder (CV-positive group) and 153 OSAS patients without cardiovascular disorder (CV-negative group). CC, CT and TT genotype distributions between groups were similar [31 (55%), 25 (45%), 0 (0%) vs 88 (57%), 61 (40%), 4 (3%); respectively, p>0.05]. MMP-9 level was significantly higher in CV-P patients (442.7±139.3 pg/mL) than in CV-N patients (364.4±165.0 pg/mL; p=0.0018). CONCLUSION: Our results showed that the presence of MMP-9 polymorphism was not associated with cardiovascular disease. MMP-9 level was higher in OSAS patients with cardiovascular disorders than without cardiovascular disorders. Finally, MMP-9 genotype was not associated with serum MMP-9 levels.
OBJECTIVE: Obstructive sleep apnea syndrome (OSAS) is associated with increased cardiovascular morbidity and mortality. We aimed to investigate the matrix metalloproteinase-9 (MMP-9) level and MMP-9 gene polymorphism in sleep apneapatients with or without cardiovascular disease. STUDY DESIGN: Case-control study. MATERIAL AND METHODS: Two hundred nine patients [Mean age (±SD), 47 (±12) yrs; M/F, 170/39] diagnosed with sleep-disordered breathing were included in the study. Serum MMP-9 level was performed using enzyme-linked immunosorbant assay (ELISA) and MMP-9 gene polymorphism with polymerase chain reaction-restriction fragment length polymorphism. We divided the patient group into two subgroups: (1) patients with confirmed cardiovascular disease, i.e. CV-P Group and (2) patients without cardiovascular disease, CV-N Group. We compared all parameters between the two groups. RESULTS: There were 56 OSAS patients with cardiovascular disorder (CV-positive group) and 153 OSAS patients without cardiovascular disorder (CV-negative group). CC, CT and TT genotype distributions between groups were similar [31 (55%), 25 (45%), 0 (0%) vs 88 (57%), 61 (40%), 4 (3%); respectively, p>0.05]. MMP-9 level was significantly higher in CV-Ppatients (442.7±139.3 pg/mL) than in CV-Npatients (364.4±165.0 pg/mL; p=0.0018). CONCLUSION: Our results showed that the presence of MMP-9 polymorphism was not associated with cardiovascular disease. MMP-9 level was higher in OSAS patients with cardiovascular disorders than without cardiovascular disorders. Finally, MMP-9 genotype was not associated with serum MMP-9 levels.
Authors: Yüksel Peker; Jan Hedner; Jeanette Norum; Holger Kraiczi; Jan Carlson Journal: Am J Respir Crit Care Med Date: 2002-07-15 Impact factor: 21.405
Authors: E Shahar; C W Whitney; S Redline; E T Lee; A B Newman; F J Nieto; G T O'Connor; L L Boland; J E Schwartz; J M Samet Journal: Am J Respir Crit Care Med Date: 2001-01 Impact factor: 21.405
Authors: P J Pöllänen; P J Karhunen; J Mikkelsson; P Laippala; M Perola; A Penttilä; K M Mattila; T Koivula; T Lehtimäki Journal: Arterioscler Thromb Vasc Biol Date: 2001-09 Impact factor: 8.311
Authors: A N Vgontzas; D A Papanicolaou; E O Bixler; A Kales; K Tyson; G P Chrousos Journal: J Clin Endocrinol Metab Date: 1997-05 Impact factor: 5.958
Authors: B Zhang; S Ye; S M Herrmann; P Eriksson; M de Maat; A Evans; D Arveiler; G Luc; F Cambien; A Hamsten; H Watkins; A M Henney Journal: Circulation Date: 1999-04-13 Impact factor: 29.690
Authors: Johan Sundström; Jane C Evans; Emelia J Benjamin; Daniel Levy; Martin G Larson; Douglas B Sawyer; Deborah A Siwik; Wilson S Colucci; Patrice Sutherland; Peter W F Wilson; Ramachandran S Vasan Journal: Circulation Date: 2004-06-01 Impact factor: 29.690
Authors: Jana Volná; David Kemlink; Marta Kalousová; Jana Vávrová; Veronika Majerová; Otto Mestek; Jana Svarcová; Karel Sonka; Tomás Zima Journal: Med Sci Monit Date: 2011-09